While it is fair to say the biotech sector has started to feel the effects of a softening of investor risk appetite, the muted investor appetite for biotech is also perhaps due to the sector entering something of a transitional phase.
The larger commercial-stage companies that led the sector's strong performance over the past few years have matured to resemble their slower-growing pharmaceutical peers. In contrast, investor enthusiasm...
Forcing KIID and prospectus changes
Countdown to 31 October
Fallout from fund suspension continues
Artemis and Woodford
Broadening reach to wider audience